Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-Amyloid burden

Translational Psychiatry

Volumn 8, Issue 1, 2018, Pages

  Rainey Smith, Stephanie R ^a,b   Mazzucchelli, Gavin N ^c   Villemagne, Victor L ^c   Brown, Belinda M ^a,b   Porter, Tenielle ^c   Weinborn, Michael ^c   Bucks, Romola S ^c   Milicic, Lidija ^b   Sohrabi, Hamid R ^a,b   Taddei, Kevin ^a,b   Ames, David ^c   Maruff, Paul ^c   Masters, Colin L ^c   Rowe, Christopher C ^c   Salvado, Olivier ^c   Martins, Ralph N ^a,b   Laws, Simon M ^a  

^a EDITH COWAN UNIVERSITY   (Australia)

^b HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AQUAPORIN 4; BIOLOGICAL MARKER;

5' UNTRANSLATED REGION; ADULT; AGED; AGING; ARTICLE; ASTROCYTE; BODY MASS; BRAIN; CROSS-SECTIONAL STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC RISK; GENETIC VARIABILITY; GENETIC VARIATION; HUMAN; LATENT PERIOD; MALE; MEDICAL HISTORY; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PITTSBURGH SLEEP QUALITY INDEX; POLYSOMNOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP; SLEEP LATENCY; SLEEP QUALITY; SLEEP TIME; AUSTRALIA; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SLEEP DISORDER; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; AQUAPORIN 4; AUSTRALIA; BRAIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; POSITRON-EMISSION TOMOGRAPHY; SLEEP; SLEEP WAKE DISORDERS;

EID: 85042667501     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/s41398-018-0094-x     Document Type: Article

References (47)

1. Peter-Derex, L., Yammine, P., Bastuji, H. & Croisile, B. Sleep and Alzheimer's disease. Sleep. Med. Rev. 19, 29-38 (2015).
2. Wolkove, N., Elkholy, O., Baltzan, M. & Palayew, M. Sleep and aging: 1. Sleep disorders commonly found in older people. Can. Med. Assoc. J. 176, 1299-1304 (2007).
3. Ju, Y. E. S., Lucey, B. P. & Holtzman, D. M. Sleep and Alzheimer disease pathology-A bidirectional relationship. Nat. Rev. Neurol. 10, 115-119 (2014).
4. Holth, J. K., Patel, T. K. & Holtzman, D. M. Sleep in Alzheimer's disease-beyond amyloid. Neurobiol. Sleep. Circ. Rhythms 2, 4-14 (2017).
5. Brown, B. M., Rainey-Smith, S. R., Bucks, R. S., Weinborn, M. & Martins, R. N. Exploring the bi-directional relationship between sleep and beta-Amyloid. Curr. Opin. Psychiatry 29, 397-401 (2016).
6. Selkoe, D. J. & Hardy, J. A. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8, 595-608 (2016).
7. Villemagne, V. L. et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol. 12, 357-367 (2013).
8. ENTP, Bakker et al. Lymphatic clearance of the brain: Perivascular, paravascular and significance for neurodegenerative diseases. Cell Mol. Neurobiol. 36, 181-194 (2016).
9. Xie, L. et al. Sleep drives metabolite clearance from the adult brain. Science 342, 373-377 (2013).
10. Branger, P. et al. Relationships between sleep quality and brain volume, metabolism, and amyloid deposition in late adulthood. Neurobiol. Aging 41, 107-114 (2016).
11. Kang, J. E. et al. Amyloid-beta dynamics are regulated by orexin and the sleepwake cycle. Science 326, 1005-1007 (2009).
12. Brown, B. M. et al. The relationship between sleep quality and brain amyloid burden. Sleep 39, 1063-1068 (2016).
13. Kress, B. T. et al. Impairment of paravascular clearance pathways in the aging brain. Ann. Neurol. 76, 845-861 (2014).
14. Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 4, 147ra111-147ra111 (2012).
15. Jessen, N. A., Munk, A. S. F., Lundgaard, I. & Nedergaard, M. The glymphatic system: A beginner's guide. Neurochem. Res. 40, 2583-2599 (2015).
16. Lundgaard, I. et al. Glymphatic clearance controls state-dependent changes in brain lactate concentration. J. Cereb. Blood Flow. Metab. 37, 2112-2124 (2016).
17. Yang, W. et al. Aquaporin-4 mediates astrocyte response to β-Amyloid. Mol. Cell Neurosci. 49, 406-414 (2012).
18. Xiao, M. & Hu, G. Involvement of aquaporin 4 in astrocyte function and neuropsychiatric disorders. CNS Neurosci. Ther. 20, 385-390 (2014).
19. Moftakhar, P., Lynch, M. D., Pomakian, J. L. & Vinters, H. V. Aquaporin expression in the brains of patients with or without cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 69, 1201-1209 (2010).
20. Hoshi, A. et al. Characteristics of aquaporin expression surrounding senile plaques and cerebral amyloid angiopathy in Alzheimer disease. J. Neuropathol. Exp. Neurol. 71, 750-759 (2012).
21. Zeppenfeld, D. M. et al. Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains. JAMA Neurol. 74, 91-99 (2017).
22. Sorani, M. D. et al. Novel variants in human Aquaporin-4 reduce cellular water permeability. Hum. Mol. Genet. 17, 2379-2389 (2008).
23. Ellis, K. A. et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int. Psychogeriatr. 21, 672-687 (2009).
24. Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R. & Kupfer, D. J. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res. 28, 193-213 (1989).
25. Clark, C. M. et al. Use of Florbetapir-PET for imaging β-Amyloid pathology. JAMA 305, 275-283 (2011).
26. Rowe, C. C. et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31, 1275-1283 (2010).
27. Vandenberghe, R. et al. 18F-Flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann. Neurol. 68, 319-329 (2010).
28. Bourgeat, P. et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol. Aging 36, S159-S166 (2015).
29. Villemagne, V. L. et al. En attendant centiloid. Adv. Res. 2, 723-729 (2014).
30. Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under dependency. Ann. Stat. 29, 1165-1188 (2001).
31. Hayes, A. F. Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-based Approach.. (The Guilford Press, New York, NY, 2013).
32. Hayes, A. F. & Rockwood N. J. Regression-based statistical mediation and moderation analysis in clinical research: observations, recommendations, and implementation. Behav. Res. Ther. 98, 39-57 (2017).
33. Boyle, A. P. et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22, 1790-1797 (2012).
34. Mander, B. A., Winer, J. R., Jagust, W. J. & Walker, M. P. Sleep: A novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer's disease? Trends Neurosci. 39, 552-566 (2016).
35. Kanbayashi, T. et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch. Neurol. 66, 1563-1566 (2009).
36. Xu, L. et al. Short or long sleep duration is associated with memory impairment in older Chinese: The Guangzhou Biobank Cohort Study. Sleep 34, 575-580 (2011).
37. Potvin, O. et al. Sleep quality and 1-year incident cognitive impairment in community-dwelling older adults. Sleep 35, 491-499 (2012).
38. Schmutte, T. et al. The relation between cognitive functioning and selfreported sleep complaints in nondemented older adults: Results from the Bronx aging study. Behav. Sleep Med. 5, 39-56 (2007).
39. Villemagne, V. L. et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neurol. 69, 181-192 (2011).
40. Villemagne, V. L. et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol. 12, 357-367 (2013).
41. Lim, Y. Y. et al. BDNF Val66Met, Abeta amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiol. Aging 34, 2457-2464 (2013).
42. Lim, Y. Y. et al. APOE and BDNF polymorphisms moderate amyloid betarelated cognitive decline in preclinical Alzheimer's disease. Mol. Psychiatry 20, 1322-1328 (2015).
43. Lim, Y. Y. et al. APOE epsilon4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiol. Aging 36, 1239-1244 (2015).
44. Nagelhus, E. A. & Ottersen, O. P. Physiological roles of aquaporin-4 in brain. Physiol. Rev. 93, 1543-1562 (2013).
45. Sepramaniam, S., Ying, L. K., Armugam, A., Wintour, E. M. & Jeyaseelan, K. MicroRNA-130a represses transcriptional activity of aquaporin 4 M1 promoter. J. Biol. Chem. 287, 12006-12015 (2012).
46. De Bellis, M. et al. Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport. Glia 65, 790-803 (2017).
47. Mollayeva, T. et al. The Pittsburgh Sleep Quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-Analysis. Sleep Med. Rev. 25, 52-73 (2016).